Australian biotech firm All G has formed a joint venture with France-based Armor Protéines to accelerate commercial production of recombinant human and bovine lactoferrin. The partnership follows All G’s AUD 10 million convertible note raise, which will support the scale-up of its speciality protein portfolio for early-life and adult nutrition markets.
The collaboration pairs All G’s precision fermentation technology with Armor Protéines’ long-standing manufacturing capabilities and global customer reach. Armor Protéines, part of Savencia Fromage & Dairy, is one of the largest suppliers of dairy bioactives and has produced lactoferrin for decades.
The agreement sets the foundation for the commercial rollout of All G’s first human lactoferrin ingredient, expected in early 2026, and continued development of its bovine equivalent. Pilot-scale production of bovine lactoferrin has already been achieved, with high purity and consistent output reported. Human lactoferrin development is progressing with targeted purity above 95%.
Global demand for lactoferrin continues to rise as nutrition manufacturers prioritise functional proteins for immune support and more bioidentical formulations. Current supply remains restricted due to the cost and inefficiency of extracting the ingredient from cow’s milk. Precision-fermented alternatives offer an emerging route to higher volumes, more stable pricing, and expanded applications beyond premium product lines.
All G has completed self-affirmed GRAS status for adult nutrition in the United States and has secured approval for personal-care uses in China. Its bovine lactoferrin powder is scheduled for release later this year, with human lactoferrin to follow in 2026.